Kisunla 350 mg
As listed in the register: Kisunla 350 mg, Konzentrat zur Herstellung einer Infusionslösung
350 mg ·
- Prescription only
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Donanemabum
- Made by
- Eli Lilly (Suisse) SA
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Leichte kognitive Störung oder leichte Demenz vom Alzheimer Typ mit nachgewiesener Alzheimer-typischer Amyloid-beta Pathologie bei heterozygoten Trägern oder Nicht-Trägern von Apolipoprotein E ε4 (ApoE ε4)
From the official label · 2026-09-30 · Swissmedic
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Eli Lilly (Suisse) SA |
|---|---|
| Active substance | Donanemabum |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Strength | 350 mg |
| Classification | N06DX05 · Pain, sleep, mood, epilepsy and the brain |
| Dispensing (as stated by the register) | Abgabekategorie A |
| Name in the register | Kisunla 350 mg, Konzentrat zur Herstellung einer Infusionslösung |
| Packs | 1 Durchstechflasche(n) |
| Zulassungsnummer | 69523 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.